source
- HHS to allocate up to $4.9 million for ibogaine research targeting PTSDThe U.S. Department of Health and Human Services announced it will provide up to $4.9 million to support research on ibogaine, a psychedelic compound. The funding is intended to explore ibogaine’s…
- Regeneron's POTS antibody shows heart-rate reduction in Phase 2, paving way for Phase 3 trialRegeneron reported results from its Phase 2 Pinnacle trial of a monoclonal antibody targeting postural orthostatic tachycardia syndrome (POTS), a disorder with no approved therapies. The trial enr…